Company
Oxford Cannabinoid Technologies Holdings Plc
Headquarters: London, United Kingdom
CEO: Dr. John Lucas Ph.D.
Market Cap
£7.2 Million
GBP as of Jan. 1, 2024
US$9.1 Million
Oxford Cannabinoid Technologies Holdings Plc Categories
United Kingdom Healthcare BiotechnologyUnited Kingdom Healthcare United Kingdom Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, focuses on the development of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing an unmodified phytocannabinoid combination for orphan indications in neuropathic pain. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Oxford Cannabinoid Technologies Holdings Plc has the following listings and related stock indices.
Stock: LSE: OCTP wb_incandescent